Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$182.50 USD

182.50
NA

+3.05 (1.70%)

Updated Jul 20, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Income Statements

Fiscal Year end for Alexion Pharmaceuticals, Inc. falls in the month of December .

All items in Millions except EPS data.

12/31/20 12/31/19 12/31/18 12/31/17 12/31/16
Sales 6,070 4,991 4,131 3,551 3,084
Cost Of Goods 554 395 374 454 258
Gross Profit 5,516 4,597 3,757 3,097 2,826
Selling & Adminstrative & Depr. & Amort Expenses 4,884 2,476 3,487 2,470 2,159
Income After Depreciation & Amortization 632 2,120 270 627 667
Non-Operating Income 41 136 71 19 6
Interest Expense 105 78 98 98 97
Pretax Income 569 2,179 242 548 576
Income Taxes -34 -226 165 105 177
Minority Interest 0 0 0 0 0
Investment Gains/Losses 0 0 0 0 0
Other Income/Charges 0 0 0 0 0
Income From Cont. Operations 603 2,404 78 443 399
Extras & Discontinued Operations 0 0 0 0 0
Net Income 603 2,404 78 443 399
Depreciation Footnote 12/31/20 12/31/19 12/31/18 12/31/17 12/31/16
Income Before Depreciation & Amortization 3,015 2,497 675 1,243 1,148
Depreciation & Amortization (Cash Flow) 2,383 377 405 616 481
Income After Depreciation & Amortization 632 2,120 270 627 667
Earnings Per Share Data 12/31/20 12/31/19 12/31/18 12/31/17 12/31/16
Average Shares 222.00 224.80 224.50 225.40 227.00
Diluted EPS Before Non-Recurring Items 11.60 9.74 7.09 5.16 3.78
Diluted Net EPS 2.72 10.70 0.35 1.97 1.76

Fiscal Year end for Alexion Pharmaceuticals, Inc. falls in the month of December .

All items in Millions except EPS data.

6/30/21 3/31/21 12/31/20 9/30/20 6/30/20
Sales NA 1,636.50 1,591.80 1,588.70 1,444.60
Cost Of Goods NA 125.40 152.20 144.70 144.90
Gross Profit NA 1,511.10 1,439.60 1,444.00 1,299.70
SG&A, R&D, and Dept/Amort Expenses 0.00 874.90 817.50 759.10 2,669.90
Income After SG&A, R&D, and Dept/Amort Expenses 0.00 636.20 622.10 684.90 -1,370.20
Non-Operating Income NA -6.50 -3.80 9.60 41.70
Interest Expense NA 27.10 27.70 27.60 23.60
Pretax Income NA 602.60 590.60 666.90 -1,352.10
Income Taxes NA 113.40 54.80 88.80 -284.00
Minority Interest NA -146.80 0.00 0.00 0.00
Investment Gains/Losses NA 0.00 0.00 0.00 0.00
Other Income/Charges NA 0.00 0.00 0.00 0.00
Income From Cont. Operations NA 489.20 535.80 578.10 -1,068.10
Extras & Discontinued Operations NA 0.00 0.00 0.00 0.00
Net Income NA 636.00 535.80 578.10 -1,068.10
Earnings Per Share Data 6/30/21 3/31/21 12/31/20 9/30/20 6/30/20
Average Shares NA 222.60 221.30 220.60 220.60
Diluted EPS Before Non-Recurring Items NA 3.25 2.72 3.07 2.87
Diluted Net EPS NA 2.86 2.44 2.62 -4.84